Moreover, schaftoside can strongly bind with cyclin-dependent kinase 1 of BPH (NlCDK1) and inhibits the activation of NlCDK1 as a kinase by suppressing phosphorylation on its Thr-14 site [64]. Here, CDK1 is linked to benign prostatic hyperplasia.